Researcher
Franki Speleman
- Disciplines:Cell signalling, Cellular interactions and extracellular matrix, Cytoskeleton, Epigenetics, Cell death, Cell division, Cell growth and development, Cell movement, Transcription and translation, Medical epigenomics, Medical metagenomics, Medical genomics, Genetics, Molecular and cell biology not elsewhere classified, Intracellular compartments and transport, Membrane structure and transport, Posttranslational modifications, Stem cell biology, Structural biology, Immunogenetics, Clinical genetics and molecular diagnostics
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
1 - 10 of 90
- Spatial-omics deciphering of cellular and molecular responses to enhanced MYCN/ATR-CHK1 synthetic lethality in high-risk neuroblastomaFrom1 Jan 2023 → TodayFunding: FWO research project
- Single-cell and spatial multi-omics exploration of tumor intrinsic and microenvironment responses to ALK-ATR-CHK1-RRM2 axis drugging in neuroblastomaFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Stichting tegen Kanker: "Agreement for the acquisition of an Advanced Technology Equipment Year 2022"From1 Jul 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Preclinical evaluation of combined RRM2/DNA damage response signaling as therapy for high-risk neuroblastomaFrom1 Feb 2022 → TodayFunding: Nonprofit institution or equivalents
- Replicatievork protectiefactoren als nieuwe doelwitten voor combinatietherapie en immunomodulering (REINFORCE)From1 Jan 2022 → 31 Dec 2022Funding: Nonprofit institution or equivalents
- The role of the SOX11 lineage-dependency factor as epigenetic master regulator in neuroblastomaFrom1 Oct 2021 → TodayFunding: BOF - projects
- Scrutinizing selective Aurora kinase A inhibition as a novel therapeutic strategy for neuroblastomaFrom1 Mar 2021 → 28 Feb 2023Funding: Foundations, funds and other with scientific goal
- Translational inhibition as novel therapeutic target in neuroblastoma: deciphering the molecular targets and dependencies of silvestrol inhibition (Carolina Nunes)From1 Jan 2021 → 31 Dec 2021Funding: Nonprofit institution or equivalents
- Replicative stress resistance modelling and therapeutic targeting in neuroblastomaFrom1 Jan 2021 → TodayFunding: Other international institutions, not mentioned elsewhere
- The role of BRIP1 in MYCN driven neuroblastoma formation: from mechanism to druggingFrom1 Jan 2021 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
Publications
1 - 10 of 61
- Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma(2023)
Authors: Jordan F. Hastings, Sharissa L. Latham, Alvin Kamili, Madeleine S. Wheatley, Jeremy Z. R. Han, Marie Wong-Erasmus, Monica Phimmachanh, Max Nobis, Chiara Pantarelli, Antonia L. Cadell, et al.
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA(2022)
Authors: Vanessa Vermeirssen, Jill Deleu, Annelien Morlion, Celine Everaert, Jilke De Wilde, Jasper Anckaert, Kaat Durinck, Justine Nuytens, Muhammad Rishfi, Franki Speleman, et al.
- MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation(2021)
Authors: Jolien De Wyn, Mark W. Zimmerman, Nina Weichert-Leahey, Carolina de Carvalho Nunes, Belamy B. Cheung, Brian J. Abraham, Anneleen Beckers, Pieter-Jan Volders, Bieke Decaesteker, Daniel R. Carter, et al.
- MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells(2021)
Authors: Sofia Zanotti, Suzanne Vanhauwaert, Christophe Van Neste, Volodimir Olexiouk, Jolien Van Laere, Marlies Verschuuren, Joni Van der Meulen, Liselot Mus, Kaat Durinck, Laurentijn Tilleman, et al.
- Distinct Notch1 and BCL11B requirements mediate human γδ/αβ T cell development(2020)
Authors: Anne-Catherine Dolens, Kaat Durinck, Marieke Lavaert, Joni Van der Meulen, Imke Velghe, Jelle De Medts, Karin Weening, Juliette Roels, Katrien De Mulder, Pieter-Jan Volders, et al.
- The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness(2020)
Authors: Liselot Mus, Irina Lambertz, Shana Claeys, Candy Kumps, Wouter Van Loocke, Christophe Van Neste, Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys, et al.
- Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma(2020)
Authors: Lucas Moreno, Giuseppe Barone, Steven G. DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Franki Speleman, Louis Chesler, et al.
Pages: 52 - 68 - Purification of high-quality RNA from a small number of fluorescence activated cell sorted zebrafish cells for RNA sequencing purposes(2019)
Authors: Siebe Loontiens, Lisa Depestel, Suzanne Vanhauwaert, Givani Dewyn, Charlotte Gistelinck, Karen Verboom, Wouter Van Loocke, Filip Matthijssens, Andy Willaert, Jo Vandesompele, et al.
- Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing(2019)
Authors: Charlotte Derpoorter, Karl Vandepoele, Araceli Diez Fraile, Katrien Vandemeulebroecke, Bram De Wilde, Franki Speleman, Nadine Van Roy, Tim Lammens, Genevieve Laureys
- ALK positively regulates MYCN activity through repression of HBP1 expression(2019)
Authors: Shana Claeys, Geertrui Denecker, Kaat Durinck, Bieke Decaesteker, Liselot Mus, Siebe Loontiens, Suzanne Vanhauwaert, Kristina Althoff, Caroline Wigerup, Daniel Bexell, et al.
Pages: 2690 - 2705
Patents
1 - 1 of 1